Introduction
============

With the development of diagnostic and interventional technology, the number of patients in whom contrast media (CM) are administered is continuously increasing. Those patients receiving intravascular CM administration are at risk of contrast-induced nephropathy (CIN). As one of the most common types of hospital-acquired kidney injury (accounting for 11--12% of all cases) ([@b1-etm-0-0-7566]), CIN is usually defined as an increase in serum creatinine (SCr) levels by ≥0.5 mg/dl or ≥25% within 48 or 72 h following CM exposure ([@b2-etm-0-0-7566]). Numerous factors may affect the risk of CIN, including age, hypertension, anemia, DM, atrial fibrillation, pre-existing renal dysfunction, insufficient circulation volume, type and volume of contrast agents and concomitant administration of nephrotoxic agents ([@b3-etm-0-0-7566]--[@b6-etm-0-0-7566]).

CIN may lead to dialysis, prolonged hospitalization and even increased mortality ([@b7-etm-0-0-7566],[@b8-etm-0-0-7566]). Effective prevention strategies are urgently required in clinics. By now, peri-procedural hydration with saline, administration of only the minimum required volume of CM, usage of low- or iso-osmolar CM and removal of nephrotoxic drugs have been widely accepted as methods to prevent CIN ([@b9-etm-0-0-7566]--[@b11-etm-0-0-7566]). Among the preventive medicines, adenosine antagonists (AAs) are of great interest. Animal studies have demonstrated that AAs increase renal blood flow and the glomerular filtration rate (GFR) after CM exposure by interrupting adenosine-induced vasoconstriction ([@b12-etm-0-0-7566]). However, several randomized controlled trials (RCTs) and meta-analyses have not consistently indicated a benefit of AAs in CIN prevention ([@b13-etm-0-0-7566]--[@b15-etm-0-0-7566]). Among those meta-analyses, only the most recent one suggested that AAs reduce the incidence of CIN ([@b15-etm-0-0-7566]). However, when a traditional meta-analysis is updated with new trials, the risk of a false-positive or false-negative result increases due to repeated significance testing ([@b16-etm-0-0-7566],[@b17-etm-0-0-7566]). To deal with this problem, trial sequential analysis (TSA) was recommended by the Copenhagen trial unit. As an interim analysis in a single trial, TSA may provide an information size calculation to ensure the reliability of the pooled estimate ([@b18-etm-0-0-7566],[@b19-etm-0-0-7566]). Furthermore, in TSA, the monitoring boundaries adjusted by random errors may detect the possibility of a false-positive or false-negative result before the required information size (RIS) is achieved ([@b20-etm-0-0-7566],[@b21-etm-0-0-7566]).

To determine the effect of AA in preventing CIN, an updated meta-analysis with inclusion of several recently published RCTs was performed. Furthermore, given the small sample sizes of the published trials and the dangers of overestimating the efficacy with traditional meta-analyses, TSA was also performed to assess the reliability of the pooled estimates.

Materials and methods
=====================

### Search strategy

The literature search was performed using the Medline, Embase, Web of Science and Cochrane databases to retrieve all RCTs on AAs in preventing CIN published until December 31, 2017 by two investigators (HZ and QZ). The search terms were 'adenosine antagonists', 'theophylline', 'aminophylline', 'contrast-induced nephropathy', 'contrast-induced nephrotoxicity', 'contrast-medium nephrotoxicity', 'contrast medium-induced nephropathy', 'contrast-induced acute kidney injury', 'contrast-associated acute kidney injury' and 'contrast-associated nephropathy'. Trials were limited to those with human subjects only. A manual search was then performed (by HZ and QZ) on the results provided by the aforementioned databases. Before retrieving the full texts, the authors of the current study reviewed the titles and abstracts first. Full texts, rather than abstracts or meeting proceedings, were included. The references of the articles retrieved were also reviewed to identify potential trials for inclusion.

### Selection criteria

Studies that met the following criteria were included: RCTs referring to CIN prevention; the intervention was AAs vs. control; aside from AA usage, there was no different intervention between the two arms in each trial; incidence of CIN must be reported.

### Data extraction and quality assessment

Two investigators (HZ and QZ) separately extracted data from all of the primary studies meeting the selection criteria. The following information of each study was assembled: Sample size, rate of diabetes mellitus (DM), type and dose of CM, baseline renal function, outcome measures, protocols for the treatment with adenosine receptor antagonists and hydration protocols. The primary outcome measure was the development of CIN, defined as an increase in the SCr level by ≥0.5 mg/dl or ≥25% within 48--72 h following CM exposure ([@b2-etm-0-0-7566]). The secondary outcome measure was the SCr level after CM administration. Items that were used to assess the quality of studies included methods of randomization, methods of blinding, placebo control, reporting of losses to follow-up and reasons for losses to follow-up. The overall quality of studies was evaluated by determining the Jadad scores ([@b22-etm-0-0-7566]). In the case of any disagreement on the extracted data, a third reviewer (XL) would adjudicate.

### Meta-analysis

Effect sizes for dichotomous data (incidence of CIN) were presented as risk ratios (RRs) and 95% confidence intervals (CIs), and for continuous data (SCr levels after CM administration), effect sizes were presented as the standardized mean differences (SMDs) and 95% CIs. Heterogeneity was reported using I^2^ statistics, with values of 0--30%, 31--50% and \>50% representing low, moderate and significant heterogeneity, respectively. For low heterogeneity, a fixed-effects model was used; otherwise, a random-effects model was used. The meta-analysis was performed using STATA version 12.0 (StataCorp LP, College Station, TX, USA).

### Publication bias and sensitivity analysis

Begg\'s test and Egger\'s test were performed to assess publication bias. A Begg\'s funnel plot was also generated. Sensitivity analysis was used to assess the effect of an individual study on the pooled estimate by removing one study at a time.

### Meta-regression and subgroup analysis

Meta-regression was performed to identify the underlying sources of heterogeneity, which included sample sizes, volumes and osmotic pressures of CM, baseline renal function, proportion of patients with DM, type and dose of AAs, routes of AA administration, study quality and peri-procedural hydration protocols. Subgroup analyses were also performed according to sample size, osmotic pressure of CM, baseline renal function and study quality.

### Cumulative meta-analysis

Cumulative analysis was performed to observe the tendency of the pooled RRs for the incidence of CIN according to the publication year.

### Trial sequential analysis

Meta-analyses are commonly updated when new evidence appears. However, repetitive testing of accumulating data runs the risk of producing random errors. To deal with this problem, TSA is used, in which the monitoring boundaries may avoid false-positive results and provide the benefit or futility of an intervention as early as possible. In the present study, the TSA of the incidence of CIN was performed using the TSA program version 0.9 beta ([www.ctu.dk/tsa](www.ctu.dk/tsa)) with α=5% and 1-β=80%. The anticipated relative risk reduction was based on the pooled estimate of available trials. If the Z-curve crossed the conventional boundary of significance (Z=±1.96, P\<0.05) but not the trial sequential significance boundary, the pooled estimate was considered to be at risk of false-positive results. Correspondingly, if the Z-curve neither crossed the conventional boundary of significance nor the trial sequential futility boundary, the pooled estimate was considered to be at risk of false-negative results. However, when the Z-curve crossed the RIS or the monitoring boundaries before the RIS is achieved, the pooled estimate was considered to be sufficiently reliable to make a firm conclusion ([@b20-etm-0-0-7566]).

Results
=======

### Identification of studies

From the initial literature search, 699 potentially relevant articles were identified. After the titles and abstracts of those articles were reviewed independently, 24 articles were regarded to be potentially qualified for inclusion. The full texts of those articles were searched. Subsequently, seven trials were excluded from the meta-analysis for various reasons (e.g., non-RCT studies, no reporting of CIN incidence, letters). Finally, 17 RCTs were identified and analyzed. The selection process of the present meta-analysis is presented in [Fig. 1](#f1-etm-0-0-7566){ref-type="fig"}.

### Features of studies included

The baseline characteristics of the 17 studies included are presented in [Table I](#tI-etm-0-0-7566){ref-type="table"}. These RCTs included 1,483 patients in total. The number of participants in each trial ranged from 30 to 280 ([@b23-etm-0-0-7566]--[@b39-etm-0-0-7566]). The percentage of patients with DM ranged from 0 to 100%. A total of 3 studies used aminophylline ([@b24-etm-0-0-7566],[@b33-etm-0-0-7566],[@b36-etm-0-0-7566]) and the others used theophylline ([@b23-etm-0-0-7566],[@b25-etm-0-0-7566],[@b32-etm-0-0-7566],[@b34-etm-0-0-7566],[@b35-etm-0-0-7566],[@b37-etm-0-0-7566]--[@b39-etm-0-0-7566]). Most studies included used iso- or low-osmolar CM, except for one study that used high-osmolar CM ([@b27-etm-0-0-7566]). AAs were administered either intravenously or orally in those trials. In 9 studies, CIN was defined as an increase in SCr levels by ≥0.5 mg/dl from baseline ([@b25-etm-0-0-7566],[@b26-etm-0-0-7566],[@b28-etm-0-0-7566]--[@b30-etm-0-0-7566],[@b32-etm-0-0-7566],[@b33-etm-0-0-7566],[@b36-etm-0-0-7566],[@b38-etm-0-0-7566]). In two studies, CIN was defined as a ≥25% increase in SCr levels from baseline ([@b24-etm-0-0-7566],[@b27-etm-0-0-7566]), and CIN was defined as either in five studies ([@b31-etm-0-0-7566],[@b34-etm-0-0-7566],[@b35-etm-0-0-7566],[@b37-etm-0-0-7566],[@b39-etm-0-0-7566]). In most studies, there was no difference in the baseline SCr between the AA and control groups ([@b23-etm-0-0-7566],[@b24-etm-0-0-7566],[@b26-etm-0-0-7566]--[@b33-etm-0-0-7566],[@b35-etm-0-0-7566]--[@b39-etm-0-0-7566]). However, in two studies, the baseline SCr was unfavorable for the AA group ([@b25-etm-0-0-7566],[@b34-etm-0-0-7566]).

### Quality assessment of trials

Of the trials included, 4 exhibited high quality (Jadad scores ≥3) ([@b25-etm-0-0-7566],[@b29-etm-0-0-7566],[@b35-etm-0-0-7566],[@b39-etm-0-0-7566]). The other studies were identified as having low quality due to lack of randomization processes, methods for blinding or losses to follow-up (Jadad scores \<3) ([@b23-etm-0-0-7566],[@b24-etm-0-0-7566],[@b26-etm-0-0-7566]--[@b28-etm-0-0-7566],[@b30-etm-0-0-7566]--[@b34-etm-0-0-7566],[@b36-etm-0-0-7566]--[@b38-etm-0-0-7566]). The overall quality of studies assessed by the Jadad scores is presented in [Table II](#tII-etm-0-0-7566){ref-type="table"}.

### Publication bias

According to Begg\'s test (P=0.773) and Egger\'s test (P=0.760), there was no publication bias across the included trials. The funnel plot is presented in [Fig. 2](#f2-etm-0-0-7566){ref-type="fig"}. Sensitivity analysis indicated that no single trial significantly influenced the pooled estimate.

### Efficacy of AA to reduce the incidence of CIN

A total of 1,483 patients were included from 17 RCTs reporting data on the incidence of CIN, with 737 and 746 patients allocated to the AA and control groups, respectively. The overall incidence of CIN was 8.90%. CIN occurred in 5.83 and 11.93% of the subjects in the AA and control groups, respectively. There was moderate heterogeneity across the studies (I^2^=47.4%; P=0.016) and therefore, a random-effects model was used for meta-analysis. The pooled result revealed that AAs significantly reduced the incidence of CIN (RR=0.53; 95% CI, 0.29--0.95; P=0.034; [Fig. 3](#f3-etm-0-0-7566){ref-type="fig"}).

Meta-regression revealed that the sample size (≥70 vs. \<70; P=0.180), volume (≥150 vs. \<150 ml; P=0.827) and osmotic pressures of CM (P=0.708), baseline renal function (≥1.5 vs. \<1.5 mg/dl; P=0.210), proportion of subjects with DM (≥50 vs. \<50%; P=0.635), type of AA (theophylline vs. aminophylline; P=0.672) and dose of theophylline and aminophylline (\>250 vs. ≤250 mg; P=0.180), route of AA administration (oral vs. intravenous; P=0.239), study quality (Jadad scores, ≥3 vs. \<3; P=0.205), and peri-procedural hydration protocols (with hydration vs. without hydration; P=0.936) did not explain for the heterogeneity of the CIN prevention effect of AAs across studies. Subgroup analyses indicated that AAs reduced the incidence of CIN in trials with a sample size of ≥70 (RR=0.34; 95% CI, 0.14--0.81; P=0.015; [Fig. 4](#f4-etm-0-0-7566){ref-type="fig"}), baseline SCr \<1.5 mg/dl (RR=0.36; 95% CI, 0.14--0.89; P=0.028; [Fig. 5](#f5-etm-0-0-7566){ref-type="fig"}), and of low quality (RR=0.41; 95% CI, 0.21--0.83; P=0.013; [Fig. 6](#f6-etm-0-0-7566){ref-type="fig"}), but not in trials with sample sizes \<70 (RR=0.81; 95% CI, 0.38--1.71; P=0.581; [Fig. 4](#f4-etm-0-0-7566){ref-type="fig"}), baseline SCr ≥1.5 mg/dl (RR=0.76; 95% CI, 0.38--1.51; P=0.435; [Fig. 5](#f5-etm-0-0-7566){ref-type="fig"}) and of high quality (RR=1.07; 95% CI, 0.38--3.02; P=0.901; [Fig. 6](#f6-etm-0-0-7566){ref-type="fig"}), which may in part explain for the underlying source of heterogeneity. When trials were grouped by osmotic pressure of CM, AAs did not significantly reduce the incidence of CIN neither in trials using low-osmolar CM (RR=0.62; 95% CI, 0.32--1.20; P=0.159; [Fig. 7](#f7-etm-0-0-7566){ref-type="fig"}) nor in trials using iso-osmolar CM (RR=1.03; 95% CI, 0.06--17.07; P=0.981; [Fig. 7](#f7-etm-0-0-7566){ref-type="fig"}). However, since only one trial used high-osmolar CM ([@b27-etm-0-0-7566]), no pooled analysis was possible, although the trial did indicate a significant decrease in the incidence of CIN by theophylline. Furthermore, in another trial, patients receiving either or low- and iso-osmolar CM were assessed ([@b34-etm-0-0-7566]). This trial did not specify which of the patients were treated by low- and iso-osmolar CM. Thus, in this trial, although administration of theophylline significantly reduces the incidence of CIN, the effects of AAs on the CIN induced by different osmotic pressures of CM could not be analyzed separately.

As the studies were added one by one, the cumulative meta-analysis indicated that the value of the pooled RRs was unstable and the corresponding 95% CIs did not become narrower, at times even with a P\>0.05 ([Fig. 8](#f8-etm-0-0-7566){ref-type="fig"}).

In the TSA, the anticipated relative risk reduction, which was based on the pooled estimate of available trials, was 47% for the incidence of CIN. The RIS of 1,778 was not reached. In addition, the cumulative Z-curve crossed the conventional boundary for benefit (P=0.05) but not the trial sequential monitoring boundary for benefit, indicating a \>5% false-positive risk for the result of a 47% reduction in the incidence of CIN with AAs vs. control ([Fig. 9](#f9-etm-0-0-7566){ref-type="fig"}). TSA was also exclusively performed in high-quality studies. The RIS was not reached and the Z-curve did not cross the conventional or trial sequential significance boundary ([Fig. 10](#f10-etm-0-0-7566){ref-type="fig"}).

### SCr level after CM administration

Among the studies included in the present meta-analysis, three trials did not contain data on the SCr level after CM administration. A total of 12 trials reported the SCr levels at 48 h after CM administration. Only two trials reported on the SCr levels at 72 h after CM administration. Thus, a pooled analysis on the SCr levels at 48 h after CM administration was performed, revealing and a significant reduction in the AA vs. control group (SMD, −0.24 mg/dl; 95% CI, −0.44 to −0.04; P=0.019; I^2^=62.3%; [Fig. 11](#f11-etm-0-0-7566){ref-type="fig"}).

### Dialysis and mortality

A total of 10 trials reported on the cases that required dialysis after CM administration. Out of 501 patients in the AA group, 3 (0.60%) required dialysis, while none of the 517 patients in the control group required dialysis. In-hospital mortality was reported by only four trials. Mortality occurred in 1 (0.69%) of 145 patients in the AA group and 3 (2.07%) of 145 patients in the control group. With those low dialysis and mortality rates, it was impossible to perform meta-analyses on these two outcome measures.

Discussion
==========

The present study included 17 RCTs, and of 1,483 the participants, 132 experienced CIN \[AA group: 43/737 (5.83%); control group: 89/746 (11.93%)\]. The meta-analysis suggested that AAs significantly reduced the risk of CIN and the SCr level after CM exposure. In addition, TSA indicated that the trials included failed to provide firm evidence for a 47% relative risk reduction in the incidence of CIN.

The pathophysiological mechanism of CIN remain incompletely understood. It is widely accepted that the direct toxicity of CM, reduced renal blood flow caused by vasoconstrictors and oxidative stress caused by reactive oxygen species are mainly responsible for the development of CIN. The direct toxicity of CM toward renal tubule cells is the primary factor. When irritated by CM, renal tubule cells release various vasoconstrictors and generate reactive oxygen species that induce programmed cell death ([@b40-etm-0-0-7566],[@b41-etm-0-0-7566]). Adenosine is the most important vasoconstrictor involved in CIN, which causes vasoconstriction of the vas afferens by activating adenosine 1 receptor ([@b42-etm-0-0-7566]). Thus, by blocking adenosine 1 receptor, AAs increase renal blood flow and the GFR ([@b43-etm-0-0-7566]).

Several clinical studies have investigated AAs for preventing CIN. However, contradictory results were obtained. Due to the small sample sizes of those studies, meta-analyses were performed to determine the protective effect of AAs. There have been three previous meta-analyses in this field. The meta-analysis of seven RCTs by Ix *et al* ([@b13-etm-0-0-7566]) indicated that AA administration caused a decrease in the SCr levels after CM exposure (SMD= −0.13 mg/dl; 95% CI, −0.22 to −0.06), but they did not assess the incidence of CIN as an outcome. A later meta-analysis including nine RCTs by Bagshaw and Ghali ([@b14-etm-0-0-7566]) reported that AAs did not reduce the incidence of CIN (odds ratio, 0.40; 95% CI, 0.14--1.16) but improved renal function after CM exposure compared with the controls (SCr, SMD= −0.17 mg/dl; 95% CI, −0.28 to −0.06). The most recent meta-analysis of 13 RCTs by Dai *et al* ([@b15-etm-0-0-7566]) indicated that AAs not only improved renal function after CM exposure (SCr, SMD= −0.31 mg/dl; 95% CI, −0.50 to −0.11) but also reduced the incidence of CIN (RR=0.48; 95% CI, 0.26--0.89). However, as meta-analyses are updated, the false-positive risk increases. In meta-analyses, a single significance test can be considered reliable once the required information size is surpassed ([@b20-etm-0-0-7566],[@b21-etm-0-0-7566]). However, meta-analyses are often performed before required information sizes are reached and are commonly updated when new trials are published. When meta-analyses are updated (before required information sizes are reached), they are repeatedly subjected to the significance testing over time. The repeated significance testing on accumulating data is known to inflate the overall false-positive risk. Simulation studies suggest that if repeated significance testing is done in meta-analyses and P\<0.05 was considered to indicate a statistical significant difference, then the actual false-positive risk will be between 10 and 30% ([@b17-etm-0-0-7566]). This phenomenon is commonly known as 'multiplicity due to repeated significance testing' ([@b17-etm-0-0-7566]). TSA may help minimize the risk of a false-positive or false-negative result in a meta-analysis by RISs and monitoring boundaries. In the present study, the TSA on the incidence of CIN indicated that the Z-curve neither crossed the trial sequential significance boundary nor reached RIS, indicating that it was not possible to draw a reliable conclusion of a 47% reduction in the incidence of CIN and another 295 subjects were required to reach the RIS. Some of the included studies were indicated to be of low quality. To minimize the effects of these low-quality studies on the results of the meta-analysis, TSA was repeated with only high-quality studies included. This did not markedly alter the results of the analysis, and the results still implied that the benefit of AAs in CIN could not be reliably determined.

Using regression analysis, Dai *et al* ([@b15-etm-0-0-7566]) indicated that the baseline SCr and study quality partly explained for the heterogeneity in their meta-analysis. However, in the present study, no source of heterogeneity was detected by regression analysis. This may have been caused by the newly added articles. Compared with the meta-analysis by Dai *et al* ([@b15-etm-0-0-7566]), the present study included four other trials. The baseline SCr was \<1.5 mg/dl in all those trials. The sample sizes of those articles ranged from 40 to 101 and one of the studies was of high quality. Furthermore, the quality of trials in previous meta-analyses was reviewed. One study that was of high quality was originally evaluated as having low quality. Furthermore, although no source of heterogeneity was detected by regression analysis, subgroup analyses indicated that AAs tended to exhibit a greater prevention effect in trials with sample sizes of ≥70, baseline SCr of \<1.5 mg/dl and low quality. However, the significant benefit in low-quality studies may be due to underlying bias. TSA revealed that 1,836 patients from high-quality studies were required to draw a firm conclusion.

Attention should be paid to the safety of AAs. AAs may induce adverse reactions and malignant arrhythmia is of particular concern. In the present meta-analysis, six articles including 658 subjects reported on the side effects of AAs ([@b26-etm-0-0-7566],[@b29-etm-0-0-7566],[@b30-etm-0-0-7566],[@b35-etm-0-0-7566],[@b38-etm-0-0-7566],[@b39-etm-0-0-7566]). Some of those subjects experienced coronary heart disease, heart failure and renal insufficiency, all of whom were at high risk for arrhythmia induced by AAs. However, there was only one case of side effects during the experimental period, namely of transient sinus tachycardia after AA administration ([@b26-etm-0-0-7566]), but no malignant arrhythmia occurred. Previous studies indicated that the side effects of AAs were likely to occur only with serum concentrations of \>20 g/ml ([@b44-etm-0-0-7566]). Therefore, the dosage and speed of AA administration should be controlled, particularly when given intravenously. Slow infusion of 250 mg theophylline or aminophylline over 30 min may be recommended.

Of note, the present study had several limitations. First, the limited number of high-quality studies may have limited the reliability and credibility of the pooled results. Furthermore, only few trials included in the present meta-analysis reported on the side effects of AAs. Therefore, no pooled results were available to assess the safety of AAs, which may induce arrhythmias in patients with coronary heart disease and heart failure. Finally, few trials were designed to assess the effect of AAs on mortality. Thus, the present meta-analysis did not provide any evidence regarding those important outcomes.

In conclusion, meta-analysis of the available data from the RCTs indicated a significant reduction in the incidence of CIN and the SCr levels with AAs vs. control for patients receiving CM. However, TSA on the incidence of CIN detected the risk of a false-positive result, indicating that more evidence is required to ensure the benefit of AAs in preventing CIN. Future studies should be of high quality and investigate the effect of AAs on clinically relevant outcomes, including in-hospital morbidity, mortality and the requirement for dialysis.
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![Subgroup analysis according to sample sizes. The diamonds indicate the pooled RRs and their 95% CI. The horizontal lines indicate the 95% CI of RRs in each trail. The squares indicate RRs in each trail and the weight of each trial. RR, risk ratio; CI, confidence interval.](etm-18-01-0085-g03){#f4-etm-0-0-7566}
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![Subgroup analysis according to study quality. The diamonds indicate the pooled RRs and their 95% CI. The horizontal lines indicate the 95% CI of RRs in each trail. The squares indicate RRs in each trail and the weight of each trial. RR, risk ratio; CI, confidence interval.](etm-18-01-0085-g05){#f6-etm-0-0-7566}
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![Cumulative meta-analysis of the incidence of contrast-induced nephropathy. The horizontal lines indicate the 95% CI of the pooled RRs until the published year. RR, risk ratio; CI, confidence interval.](etm-18-01-0085-g07){#f8-etm-0-0-7566}

![Trial sequential analysis of 17 trials on the incidence of CIN. The required information size was 1,778, based on an anticipated intervention effect resembling a relative risk reduction of 47%. The control event proportion was estimated from the incidence of CIN in the control group and a diversity of 54%, α=5% and 1-β=80%. The required information size was not reached and the Z-curve crossed only the conventional boundary (P\<0.05) but not the trial sequential monitoring boundary for benefit, suggesting the possibility of a false-positive result. CIN, contrast-induced nephropathy.](etm-18-01-0085-g08){#f9-etm-0-0-7566}

![Trial sequential analysis of four high-quality trials on the incidence of CIN. The required information size was 2,173, based on an anticipated intervention effect of 47% relative risk reduction. The control event proportion was estimated from the incidence of CIN in the control group and a diversity of 36%, α=5%, and 1-β=80%.](etm-18-01-0085-g09){#f10-etm-0-0-7566}

![Forest plot of difference in the serum creatinine level at 48 h after contrast media administration between the adenosine antagonist and control groups. The diamond indicates the pooled SMD and its 95% CI. The horizontal lines indicate the 95% CI of SMDs in each trail. The squares indicate SMDs in each trail and the weight of each trial. SMD, standardized mean difference; CI, confidence interval.](etm-18-01-0085-g10){#f11-etm-0-0-7566}

###### 

Baseline characteristics of studies included in the present meta-analysis.

  Author (year)               Diabetes mellitus (%)   Patients (I/C)   Contrast type                Contrast medium volume (ml)   Baseline SCr (I/C)         CIN definition                         Theo or amino protocol                                                                                                                                                                  Hydration protocol                                                                                                (Refs.)
  --------------------------- ----------------------- ---------------- ---------------------------- ----------------------------- -------------------------- -------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- -----------------------
  Gandhi *et al* (1992)       NR                      21 (13/8)        Low osmolar                  NR                            NR                         NR                                     Theo 125 mg orally twice daily for 24 h prior to and 48 h after contrast exposure                                                                                                       None                                                                                                              ([@b23-etm-0-0-7566])
  Abizaid *et al* (1999)      55                      40 (20/20)       Low osmolar                  190                           1.9±0.4 vs. 2.3±0.8        SCr ↑ ≥25% within 48 h                 Amino 4 mg/kg bolus, then 0.4 mg/kg/h i.v. for 2 h prior to contrast exposure                                                                                                           0.45% saline solution 1 ml/kg/h i.v. for 12 h prior to and 12 h after contrast exposure                           ([@b24-etm-0-0-7566])
  Erley *et al* (1999)        30                      64 (35/29)       Low osmolar                  125                           1.9±0.5 vs. 1.7±0.4        SCr ↑ ≥0.5 mg/dl within 72 h           Theo 270 mg orally every morning and 540 mg orally every night from 2 days before to exposure 3 days after contrast exposure                                                            2-2.5 L fluid orally or i.v. for 24 h prior to and 24 h after contrast                                            ([@b25-etm-0-0-7566])
  Huber *et al* (2002)        34                      100 (50/50)      Low osmolar                  207                           2.07±0.94 vs. 1.92±0.76    SCr ↑ ≥0.5 mg/dl within 48 h           Theo 200 mg i.v. 30 min prior to contrast exposure                                                                                                                                      2 l/d advised                                                                                                     ([@b26-etm-0-0-7566])
  Kapoor *et al* (2002)       100                     70 (35/35)       High osmolar                 79                            1.16±0.18 vs. 1.19±0.23    SCr ↑ ≥25% within 48 h                 Theo 200 mg orally twice daily for 24 h prior to and 48 h after contrast exposure                                                                                                       0.9% saline solution 1 ml/kg/h i.v. for 12 h prior to and 12 h after contrast exposure                            ([@b27-etm-0-0-7566])
  Huber *et al* (2003)        31                      100 (50/50)      Low osmolar                  207                           1.65±0.41 vs. 1.72±0.69    SCr ↑ ≥0.5 mg/dl within 48 h           Theo 200 mg i.v. 30 min prior to contrast exposure                                                                                                                                      2 l/d advised                                                                                                     ([@b28-etm-0-0-7566])
  Dussol *et al* (2006)       28                      157 (80/77)      Low osmolar                  124                           2.42±1.28 vs. 2.35±0.95    SCr ↑ ≥0.5 mg/dl within 48 h           Theo 5 mg/kg orally in 1 dose 1 h prior to contrast exposure                                                                                                                            0.9% saline solution 15 ml/kg i.v. for 6 h prior to contrast exposure                                             ([@b29-etm-0-0-7566])
  Huber *et al* (2006)        26                      99 (49/50)       Low osmolar                  154                           1.28±0.74 vs. 1.25±0.74    SCr ↑ ≥0.5 mg/dl within 48 h           Theo 200 mg i.v. 30 min prior to contrast exposure                                                                                                                                      None                                                                                                              ([@b30-etm-0-0-7566])
  Demir *et al* (2008)        NR                      40 (20/20)       Low osmolar                  100                           0.84±0.27 vs. 0.88±0.23    SCr ↑ ≥0.5 mg/dl or ≥25% within 72 h   Theo 200 mg orally every morning from 1 day before to 1 day prior to contrast exposure                                                                                                  2 l 0.9% saline solution i.v. for 24 h prior to and 24 h after contrast exposure                                  ([@b31-etm-0-0-7566])
  Baskurt *et al* (2009)      30                      145 (72/73)      Low osmolar                  123                           1.47±0.27 vs. 1.39±0.24    SCr ↑ ≥0.5 mg/dl within 48 h           Theo 200 mg orally twice daily on the day prior to and the day of contrast exposure                                                                                                     0.9% saline solution 1 ml/kg/h i.v. for 12 h prior to and 12 h after contrast exposure                            ([@b32-etm-0-0-7566])
  Kinbara *et al* (2010)      40                      30 (15/15)       Low osmolar                  142                           0.97±0.29 vs. 0.94±0.21    SCr ↑ ≥0.5 mg/dl within 48 h           Amino 250 mg i.v. 30 min prior to contrast exposure                                                                                                                                     0.9% saline solution 1 ml/kg/h i.v. for 30 min prior to and 10 h after contrast exposure                          ([@b33-etm-0-0-7566])
  Malhis *et al* (2010)       33                      280 (128/152)    Low osmolar or iso-osmolar   141                           1.38±0.79 8 vs. 1.21±0.4   SCr ↑ ≥0.5 mg/dl or ≥25% within 48 h   Theo 200 mg orally twice daily for 24 h prior to and 48 h after contrast exposure; or theo 200 mg i.v. 30 min prior to and 200 mg orally twice daily for 48 h after contrast exposure   1--2 l sodium bicarbonate (150 mEq/l) i.v. for 12 h after contrast exposure                                       ([@b34-etm-0-0-7566])
  Matejka *et al* (2010)      75                      56 (31/25)       Iso-osmolar                  95                            2.02±0.45 vs. 2.06±0.59    SCr ↑ ≥0.5 mg/dl or ≥25% within 48 h   Theo 205.7 mg i.v. 90 min prior to contrast exposure                                                                                                                                    0.9% saline solution 0.5 ml/kg/d i.v. for 1 day after contrast exposure                                           ([@b35-etm-0-0-7566])
  Rohani (2010)               18                      60 (30/30)       Low osmolar                  205                           1.93±0.21 vs. 1.84±0.54    SCr ↑ ≥0.5 mg/dl within 48 h           Amino 250 mg i.v. 30 min prior to contrast exposure                                                                                                                                     0.9% saline solution i.v. for 3--12 h prior to 1.0--1.5 ml/kg/h and 6--24 h after contrast exposure               ([@b36-etm-0-0-7566])
  Bilasy *et al* (2012)       50                      60 (30/30)       Low osmolar                  117                           1.54±0.73 vs. 1.34±0.66    SCr ↑ ≥0.5 mg/dl or ≥25% within 72 h   Theo 200 mg i.v. 30 min prior to contrast exposure                                                                                                                                      0.9% saline solution 1 ml/kg/h i.v. for 12 h prior to and 12 h after contrast exposure                            ([@b37-etm-0-0-7566])
  Caglar *et al* (2014)       41                      101 (51/50)      Low osmolar                  100                           1.39±0.2 vs. 1.36±0.2      SCr ↑ ≥0.5 mg/dl within 48 h           Theo 200 mg orally twice daily for the day prior to and the day of contrast exposure                                                                                                    Sodium bicarbonate (154 mEq/l) 3 ml/kg/h i.v. for 1 h before and 1 ml/kg/h i.v. for 6 h after contrast exposure   ([@b38-etm-0-0-7566])
  Arabmomeni *et al* (2015)   73                      60 (28/32)       Iso-osmolar                  143                           1.08±0.22 vs. 1.08±0.22    SCr ↑ ≥0.5 mg/dl or ≥25% within 48 h   Theo 200 mg orally twice daily for 24 h prior to and 48 h after contrast exposure                                                                                                       0.9% saline solution 1 ml/kg/h i.v. for 12 h prior to and 12 h after contrast exposure                            ([@b39-etm-0-0-7566])

SCr, serum creatinine; CIN, contrast-induced nephropathy; i.v., intravenously; Theo, theophylline; NR, not reported; I/C, intervention/control group.

###### 

Quality of included studies in this meta-analysis.

  Author (year)               Jadad score^[a](#tfn2-etm-0-0-7566){ref-type="table-fn"}^   Inclusion/exclusion criteria specified   Randomization process described   Use of any blinding   Placebo control   Reported loss to follow-up   Reason for loss to follow-up provided   Baseline differences between groups   Power calculation   (Refs.)
  --------------------------- ----------------------------------------------------------- ---------------------------------------- --------------------------------- --------------------- ----------------- ---------------------------- --------------------------------------- ------------------------------------- ------------------- -----------------------
  Gandhi *et al* (1992)       2                                                           Yes                                      No                                Yes                   Yes               No                           NS                                      NS                                    No                  ([@b23-etm-0-0-7566])
  Abizaid *et al* (1999)      2                                                           Yes                                      Yes                               No                    No                Yes                          No                                      No                                    No                  ([@b24-etm-0-0-7566])
  Erley *et al* (1999)        4                                                           Yes                                      No                                Yes                   Yes               Yes                          Yes                                     Yes                                   No                  ([@b25-etm-0-0-7566])
  Huber *et al* (2002)        2                                                           Yes                                      No                                Yes                   Yes               No                           NS                                      Yes                                   No                  ([@b26-etm-0-0-7566])
  Kapoor *et al* (2002)       1                                                           Yes                                      No                                No                    No                No                           NS                                      No                                    No                  ([@b27-etm-0-0-7566])
  Huber *et al* (2003)        1                                                           Yes                                      No                                Yes                   Yes               No                           NS                                      No                                    Yes                 ([@b28-etm-0-0-7566])
  Dussol *et al* (2006)       3                                                           Yes                                      Yes                               No                    No                Yes                          Yes                                     No                                    No                  ([@b29-etm-0-0-7566])
  Huber *et al* (2006)        1                                                           Yes                                      No                                No                    No                No                           NS                                      No                                    Yes                 ([@b30-etm-0-0-7566])
  Demir *et al* (2008)        2                                                           Yes                                      No                                No                    No                Yes                          No                                      No                                    No                  ([@b31-etm-0-0-7566])
  Baskurt *et al* (2009)      2                                                           Yes                                      Yes                               No                    No                No                           NS                                      No                                    No                  ([@b32-etm-0-0-7566])
  Kinbara *et al* (2010)      1                                                           Yes                                      No                                No                    No                No                           NS                                      No                                    No                  ([@b33-etm-0-0-7566])
  Malhis *et al* (2010)       1                                                           Yes                                      Yes                               No                    No                No                           NS                                      No                                    No                  ([@b34-etm-0-0-7566])
  Matejka *et al* (2010)      5                                                           Yes                                      Yes                               Yes                   Yes               Yes                          Yes                                     No                                    Yes                 ([@b35-etm-0-0-7566])
  Rohani (2010)               2                                                           Yes                                      No                                Yes                   Yes               No                           NS                                      No                                    No                  ([@b36-etm-0-0-7566])
  Bilasy *et al* (2012)       2                                                           Yes                                      Yes                               Yes                   No                No                           NS                                      No                                    No                  ([@b37-etm-0-0-7566])
  Caglar *et al* (2014)       2                                                           Yes                                      Yes                               No                    No                No                           NS                                      No                                    No                  ([@b38-etm-0-0-7566])
  Arabmomeni *et al* (2015)   5                                                           Yes                                      Yes                               Yes                   Yes               Yes                          Yes                                     No                                    Yes                 ([@b39-etm-0-0-7566])

Jadad score range, 0--5. NS, not specified or available.
